Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,524.60GBp
20 Mar 2019
Change (% chg)

-- (--)
Prev Close
1,524.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,400,407
52-wk High
1,648.80
52-wk Low
1,269.80

Select another date:

Tue, Mar 19 2019

Photo

GSK reports positive data from trial of endometrial cancer drug

GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

GSK reports positive data from trial of endometrial cancer drug

GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

GSK reports positive data from trial of endometrial cancer drug

March 19 GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

British fraud office abandons Rolls-Royce, GSK investigations

LONDON The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".

British fraud office abandons Rolls-Royce, GSK investigations

LONDON The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".

UPDATE 2-British fraud office abandons Rolls-Royce, GSK investigations

LONDON, Feb 22 The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".

UK's Serious Fraud Office drops investigations of Rolls Royce individuals, GSK

Feb 22 Britain's Serious Fraud Office (SFO) has dropped its investigations into aero engine maker Rolls-Royce individuals and drugs giant GlaxoSmithKline, citing insufficient evidence.

Mylan launches Advair generic at one-third price

Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

Mylan launches Advair generic at one-third price

Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

Mylan launches Advair generic at one-third price

Feb 12 Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

Select another date: